

Toxoplasmosis

Selected References:

- Alvarado-Esquivel C, et al. 2015. High seroprevalence of *Toxoplasma gondii* infection in female sex workers: A case-control study. *Eur J Microbiol (Bp)*; 5(4):285-292.
- Abdoloe A, et al. 2012. Impaired reproductive function of male rats infected with *Toxoplasma gondii*. *Andrologia*; 44 Suppl 1:679-687.
- Arce-Estrada GE, et al. 2017. Report of an unusual case of anophthalmia and craniofacial cleft in a newborn with *Toxoplasma gondii* congenital infection. *BMC Infect Dis*; 17(1):459.
- Assistant Secretary for Public Affairs (ASPA). 2022. Cook to a safe minimum internal temperature. FoodSafety.gov. <https://www.foodsafety.gov/food-safety-charts/safe-minimum-internal-temperatures>.
- Bonetti A, et al. 2025. Risk of Congenital Toxoplasmosis in Newborns from Mothers with Documented Infection: Experience from Two Referral Centres. *Pathogens*; 14(2):157.
- Buonsenso D, et al. 2022. Spyramicine and Trimethoprim-Sulfamethoxazole Combination to Prevent Mother-To-Fetus Transmission of *Toxoplasma gondii* Infection in Pregnant Women: A 28-Years Single-center Experience. *Pediatr Infect Dis J*; 41(5).
- Cerisola A, et al. 2025. Congenital toxoplasmosis. *Semin Pediatr Neurol*; 54:101203.
- Codaccioni C, et al. 202. Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetuses. *Prenat Diagn*; 40(13):1741-1752.
- Cook AJC, et al. 2000. Sources of toxoplasmosis in pregnant women. *BMJ*; 321:142-147.
- Conceição AR, et al. 2021. Ocular Findings in Infants with Congenital Toxoplasmosis after a Toxoplasmosis Outbreak. *Ophthalmology*; 128(9):1346-1355.
- Cortina-Borja M, et al, & European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). 2010. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. *PLoS Med*; 7(10):e1000351.
- Couvreur J, et al. 1993. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. *Fetal Diagn Ther*; 8:45-50.
- Dadoun S, et al. 2024. Congenital toxoplasmosis of the brain caused by infection in late pregnancy. *Lancet*; 403(10431):1081-1082.
- Daffos F, et al. 1988. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. *N Engl J Med*; 318(5):271-275.
- Damar Çakırca T, et al. 2023. Toxoplasmosis: A Timeless Challenge for Pregnancy. *Trop Med Infect Dis*; 8(1):63.
- Dard C, et al. 2017. Late diagnosis of congenital toxoplasmosis based on serological follow-up: A case report. *Parasitol Int*; 66(2):186-189.
- D'Ercole C, et al. 1995. Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. *Prenat Diagn*; 15(12):1171-1175.
- Desmonts G, Couvreur J. 1974. Congenital toxoplasmosis. A prospective study of 378 pregnancies. *N Engl J Med*; 290(20):1110-6.
- Dhombres F, et al. 2017. Prognosis of fetal parenchymal cerebral lesions without ventriculomegaly in congenital toxoplasmosis infection. *Fetal Diagn Ther*; 41(1):8-14.
- Dubey JP and Jones JL. 2008. *Toxoplasma gondii* infection in humans and animals in the United States. *Int J Parasitol*; 38:1257-1278.
- Ducrot SB, et al. 2018. Neonatal fever: A puzzling case. *Arch Pediatr*; 25(7):435-438.
- Dunn D, et al. 1999. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling. *Lancet*; 353:1829-1833.
- El-Beshbishi SN, et al. 2025. The Impact of Chronic Toxoplasmosis on the Gonadotropic Gonadal Axis in Male

Rats. *Acta Parasitol*; 71(1):3.

- Elbez-Rubinstein A, et al. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. *J Infect Dis*; 199(2):280-5.
- Fallahi S, et al. 2018. An updated literature review on maternal-fetal and reproductive disorders of *Toxoplasma gondii* infection. *Gynecol Obstet Hum Reprod*; 47(3):133-140.
- Feldman DM, et al. 2016. Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy. *Clin Lab Med*; 36(2):407-419.
- Ferreira L, et al. 2024. Congenital toxoplasmosis and auditory disorders: a literature review. *Front Psychol*; 14:1286211.
- Flegr J, et al. 2014. Toxoplasmosis can be a sexually transmitted infection with serious clinical consequences. Not all routes of infection are created equal. *Med Hypotheses*; 83(3):286-289.
- Foulton W, et al. 1999. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. *Am J Obstet Gynecol*; 181(4):843-847.
- Foulton W, et al. 1999. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. *Am J Obstet Gynecol*; 180(2):410-415.
- Gilbert RE, Stanford MR. 2000. Is ocular toxoplasmosis caused by prenatal or postnatal infection. *Br J Ophthalmol*; 84(2):224-226.
- Giugno S, et al. 2020. Congenital toxoplasmotic chorioretinitis following reinfection. *Eur J Obstet Gynecol Reprod Biol*; 251:263-265.
- Groer MW, et al. 2011. Prenatal depression and anxiety in *Toxoplasma gondii* positive women. *Am J Obstet Gynecol*; 204(5):433.e1-7.
- Guerina NG, et al. 1994. Neonatal serologic screening and early treatment for congenital *Toxoplasma gondii* infection. The New England Regional *Toxoplasma* Working Group. *N Engl J Med*; 330(26):1858-63.
- Gundeslioglu OO, et al. 2024. Congenital Toxoplasmosis and Long-term Outcomes. *Turkiye Parazitol Derg*; 48(1):8-14.
- Gunturiz ML, et al. 2018. Congenital cerebral toxoplasmosis, Zika, and chikungunya virus infections: a case report. *Biomedica*; 38(2):144-152.
- Hampton MM. 2015. Congenital toxoplasmosis: A review. *Neonatal Netw*; 34(5):274-278.
- Hide G, et al. 2009. Evidence for high levels of vertical transmission in *Toxoplasma gondii*. *Parasitol*; 136:1877-1885.
- Hlaváčová J, et al. 2021. Male-to-female presumed transmission of toxoplasmosis between sexual partners. *Am J Epidemiol*; 190(3):386-392.
- Hlaváčová, Jet al. 2021, Association between latent toxoplasmosis and fertility parameters of men. *Andrology*; 9: 854-862.
- Hohlfeld P, et al. 1991. Fetal toxoplasmosis: ultrasonographic signs. *Ultrasound Obstet Gynecol*; 1(4):241-4.
- Hohlfeld P, et al. 1994. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. *N Engl J Med*; 331(11):695-699.
- Hosseini SA, et al. 2025. Latent toxoplasmosis and preeclampsia: evidence for the role of chronic infection in pregnancy complications. *BMC Pregnancy Childbirth*; 25(1):1130.
- Hunter K, et al. 1983. Prenatal screening of pregnant women for infections caused by cytomegalovirus, Epstein-Barr virus, herpesvirus, rubella, and *Toxoplasma gondii*. *Am J Obstet Gynecol*; 145:269-273.
- Hurt K, et al. 2022. Toxoplasmosis impact on prematurity and low birth weight. *PLoS One*; 17(1).
- Jones, CA. 2001. Maternal transmission of infectious pathogens in breast milk. *J Paediatr Child Health*; 37:576-582.
- Jones JL et al. 2001. Toxoplasmosis *gondii* infection in the United States: Seroprevalence and Risk Factors. *Am J Epidemiol*; 4:357-365.
- Kahn K, Kahn W. 2018. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. *Parasitol Int*; (67(6):715-721.

- Kalantari N, et al. 2021. Toxoplasma gondii infection and spontaneous abortion: A systematic review and meta-analysis. *Microb Pathog*; 158:105070.
- Kaňková Š, et al. 2015. The influence of latent toxoplasmosis on women's reproductive functions: four cross-sectional studies. *Folia Parasitol (Praha)*; 62:2015.041.
- Kaňková Š, et al. 2020. Oral sex: A new, and possibly the most dangerous, route of toxoplasmosis transmission. *Med Hypotheses*; 141:109725.
- Kazemi F, et al. 2023. Toxoplasma and Risk of Spontaneous Abortion: A Meta-Analysis in A Population of Iranian Women. *Int J Fertil Steril*; 17(1):7-11.
- Khamsian EM, et al. 2021. Toxoplasma gondii in milk of human and goat from the desert area in Central Iran. *Iran J Parasitol*; 16(4): 601-609.
- Koppe JG, et al. 1986. Results of 20-year follow-up of congenital toxoplasmosis. *Lancet*; 1:254-255.
- Li XL, et al. 2014. A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection. *PLoS One*; 9(5):e97775.
- Lopez A, et al. 2000. Preventing congenital toxoplasmosis. *MMWR Recomm Rep*; 49(RR-2):59-68.
- Lynfield R and Eaton RB. 1995. Teratogen update: Congenital toxoplasmosis. *Teratology*; 52(3):176-180.
- Maldonado YA, Read JS; Committee on Infections Diseases. 2017. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. *Pediatrics*; 139(2):e20163860.
- Malinger G, et al, 2011. Herrera M. Prenatal brain imaging in congenital toxoplasmosis. *Prenat Diagn*; 31(9):881-6.
- Marsolkova K, et al. 2018. Congenital central toxoplasmosis chorioretinitis – case study. *Cesk Slov Oftalmol*; 74(3):114-118.
- Martinez VO, et al. 2023. Impact of chronic toxoplasmosis in pregnancy: association between maternal seropositivity for Toxoplasma gondii IgG antibodies and fetal growth restriction. *Parasitol Res*; 123(1):25.
- Matini M, et al. 2026. Toxoplasmosis: sperm parameters and testosterone levels in men. *J Parasit Dis*; 50(1):244-249.
- Matsui D. 1994. Prevention, diagnosis and treatment of fetal toxoplasmosis. *Clin Perinatol*; 21(3):675-689.
- Merz E. 2004. Ultrasound in obstetrics and gynecology. Vol. 1: obstetrics. 2nd ed. New York, NY: Thieme.
- McLeod R, et al. 2014. Management of congenital toxoplasmosis. *Curr Pediatr Rep*; 2:166-194.
- Montoya JG, Liesenfeld O. 2004 Toxoplasmosis. *Lancet*. 363(9425):1965-1976.
- Montoya JC & Remington JS. 2008. Management of Toxoplasma gondii infection during pregnancy. *Clin Infect Dis*; 47(4):554-566.
- National Center for Infectious Diseases and the CDC. 2000. Preventing Congenital Toxoplasmosis. *MMWR*. 49(RR02);57-75.
- Njoh AA, et al. 2016. Fetal malformation in maternal toxoplasma and rubella co-infection in Cameroon: A case report. *J Med Case Rep*; 10(1):345.
- Nourollahpour Shiadeh M, et al. 2020. The prevalence of latent and acute toxoplasmosis in HIV-infected pregnant women: A systematic review and meta-analysis. *Microb Pathog*; 149:104549.
- Orevaoghene OE, et al. 2025. Evaluation of Maternal and Neonatal Risk Factors in the Transmission of Toxoplasmosis: A Study on the Detection of Toxoplasma gondii Antibodies in Cord Blood. *Ethiop J Health Sci*. 2025 Jul;35(4):267-273.
- Oz HS. 2017. Fetomaternal and pediatric toxoplasmosis. *J Pediatr Infect Dis*; 12(4): 202-208.
- Paquet C, Yudin MH; Society of Obstetricians and Gynaecologists of Canada. 2013. Toxoplasmosis in pregnancy: prevention, screening, and treatment. *J Obstet Gynaecol Can*; 35(1):78-81.
- Paquet C, Yudin MH. 2018. No. 285-Toxoplasmosis in pregnancy: Prevention, screening, and treatment. *J Obstet Gynaecol Can*; 40(8):e687-e693.
- Picone O, et al. 2020. Toxoplasmosis screening during pregnancy in France: Opinion of an expert panel for the CNGOF. *J Gynecol Obstet Hum Reprod*; 49(7):101814.
- Prusa A-R, et al. 2015. The Austrian toxoplasmosis register, 1992-2008. *Clin Infect Dis*; 60(2): e4-e10.

- Rajapakse S, et al. 2017. Prophylaxis of human toxoplasmosis: a systematic review. *Pathog Glob Health*; 111(7):333-342.
- Red Book: 2024–2027. Report of the Committee on Infectious Diseases (33rd Edition). *Toxoplasma gondii* Infections (Toxoplasmosis). Red book (Elk Grove Village, Ill.), p.867.
- Rehman F, et al. 2020. Unpasteurized milk consumption as a potential risk factor for toxoplasmosis in females with recurrent pregnancy loss. *J Obstet Gynaecol*; 4:1-5.
- Rico-Torres CP, et al. 2016. Is *Toxoplasma gondii* type related to clinical outcome in human congenital infection? Systematic and critical review. *Eur J Clin Microbiol Infect Dis*; 35(7):1079-1088.
- Robert-Gangneux F, Darde M-L. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev*; 25(2) :264-296.
- Rojas-Barón L, et al. 2025. Adverse impact of acute *Toxoplasma gondii* infection on human spermatozoa. *FEBS J*; 292(17):4720-4736.
- Sanders AP, et al. 2017. Ocular lesions in congenital toxoplasmosis in Santa Isabel do Ivaí, Paraná, Brazil. *Pediatr Infect Dis J*; 36(9):817-820.
- Shojaee S, et al. 2018. The relation of secondary sex ratio and miscarriage history with *Toxoplasma gondii* infection. *BMC Infect Dis*; 18(1):307.
- Simon L, et al. 2020. A case of toxoplasmosis-associated miscarriage with maternal infections four months prior to conception. *Parasitol Int*; 79:102165.
- Smit GSA, et al. 2017. Public health impact of congenital toxoplasmosis and cytomegalovirus infection in Belgium, 2013: a systematic review and data synthesis. *Clin Infect Dis*; 65(4):661-668.
- Spann MN, et al. 2017. Prenatal toxoplasmosis antibody and childhood autism. *Autism Res*; 10(5):769-777.
- Stray-Pedersen B. 1993. Toxoplasmosis in pregnancy. *Baillieres Clin Ob Gynecol*; 7(1):107-137.
- Tamma P. 2007. Toxoplasmosis. *Pediatr Rev*; 28(12):470-1.
- Torrey EF, et al. 2012. Toxoplasmosis *gondii* and other risk factors for schizophrenia: an update. *Schizophr Bull*; 38(3):642-647.
- The American College of Obstetricians and Gynecologists (ACOG). 2015, reaffirmed 2024. Practice bulletin # 151: Cytomegalovirus, Parvovirus B19, Varicella Zoster, and Toxoplasmosis in Pregnancy. *Ob Gyn* 125(6): 1510-1525.
- The Centers for Disease Control and Prevention (CDC):About Toxoplasmosis. 2025. Available at: <https://www.cdc.gov/toxoplasmosis/about/index.html>. [Accessed 3/31/26]. Clinical Overview of Toxoplasmosis. 2024. Available at: <https://www.cdc.gov/toxoplasmosis/hcp/clinical-overview/index.html>. [Accessed 3/31/26].
- Toxoplasmosis and Breastfeeding. 2025. Available at: <https://www.cdc.gov/breastfeeding-special-circumstances/hcp/illnesses-conditions/toxoplasmosis.html>. [Accessed 3/31/26].
- The Toxoplasmosis Study Group. 1990. Congenital toxoplasmosis. *Am J Dis Child*; 144:619.
- Túzkó N, et al. 2024. Associations between Fetal Symptoms during Pregnancy and Neonatal Clinical Complications with Toxoplasmosis. *Children (Basel)*; 11(9):1111.
- Villena I, et al. 1998. Prenatal diagnosis of congenital toxoplasmosis transmitted by an immunocompetent woman infected before conception. Reims Toxoplasmosis Group. *Prenat Diagn*; 18(10):1079-81.
- Walana W, et al. 2026. Prevalence, risk factors, diagnosis and outcomes of *Toxoplasma gondii* infection in pregnancy: A review. *Parasitol Int*; 110:103143.
- Wallon M, et al. 2014. Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence. *Pediatrics*; 133(3):e601-8.
- Wallon M, Peyron F. 2018. Congenital toxoplasmosis: A plea for a neglected disease. *Pathogens*; 7(1):25.
- Werner H, et al. 2017. Neuroimaging findings of congenital toxoplasmosis, cytomegalovirus, and Zika virus infections: A comparison of three cases. *J Obstet Gynaecol Can*; 39(12):1150-1155.
- Wilson CB. 1980. Development of adverse sequelae in children born with subclinical toxoplasmosis infection. *Pediatrics*; 66(5):767-774.

- Zhang F, et al. 2024. Toxoplasma gondii Causes Adverse Pregnancy Outcomes by Damaging Uterine Tissue-Resident NK Cells That Secrete Growth-Promoting Factors. J Infect Dis; 229(2):547-557.
- Zhao F, et al. 2026. Clinical characteristics and associated risk factors for diminished ovarian reserve among Chinese women: a matched case-control study. Front Endocrinol (Lausanne); 17:1767835.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 avril 2026.

Toxoplasmosis

Selected References:

- Bang Madsen K, et al. 2023. In utero exposure to ADHD medication and long-term offspring outcomes. Molecular psychiatry; 28(4):1739-1746.
- Boutroy MJ, et al. 1988. Clonidine: Placental transfer and neonatal adaption. Early Hum Dev; 17:275-286.
- Bunjes R, Schaefer C. 1993. Clonidine and breast-feeding. Clinical Pharm 12:178-9.
- Frazier, LM, et al. 2020. Emerging therapies for the treatment of neonatal abstinence syndrome. The Journal of Maternal-Fetal & Neonatal Medicine; 6:1-9.
- Horvath JS, et al. 1985. Clonidine hydrochloride a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol; 66:634-8.
- Huisjes, et al. 1986. Is clonidine a behavioural teratogen in the human? Early Hum Dev; 14:43-8.
- Khan A, et al. 1970. Clonidine (Catapres): a new anti-hypertensive agent. Cur Ther Res; 12:10.
- Liu X, et al. 2026. Clonidine compromises human sperm functions. Reproductive Toxicology; 140, 109164.
- Maina A, et al. 2014. Transdermal clonidine in the treatment of severe hyperemesis: A pilot randomized controlled trial (CLONEMESI). BJOG: An International Journal of Obstetrics & Gynaecology; 121,1556-1562.
- Mirmiran M. 1986. The importance of fetal/neonatal REM sleep. Eur J Obstet Gynecol Reprod Biol; 21:283-91.
- Rothberger S, et al. 2010. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens; 23(11):1234-40.

- Sevrez C, et al. 2014. [Transplacental or breast milk intoxication to clonidine: a case of neonatal hypotonia and drowsiness]. Arch Pediatr; 21(2):198-200.
- Stoll C, et al. 1979. Robert's syndrome and clonidine. J Med Genet; 16:486-8.
- Terada H, et al. 2005. Oral clonidine advances spermatogenesis in oligozoospermic patients with spermatogenetic maturation arrest. International journal of urology: official journal of the Japanese Urological Association; 12(9),815-820.
- Tuimala R, et al. 1985. Clonidine in the treatment of hypertension during pregnancy. Annales Chirurgiae et Gynaecologiae Supplementum; 197,47-50.
- Tsai TH, et al. 1982. Teratologic and reproductive studies of lofexidine. Arzneimittelforsch; 32:962-6.
- Zangeneh F, et al. 2022. The first report of clonidine in vivo/in vitro effects on infertile women with polycystic ovary syndrome (in vivo/in vitro study). Journal of the Institute of Obstetrics and Gynaecology; 42(5),1331-1339.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 avril 2026.

Toxoplasmosis

Selected References:

- Allocca M, et al. 2018. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 30(3):316-322.
- Asthana R, et al. 2025. Meta-analysis and systematic review on sulfasalazine/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes. Reprod Toxicol 135:108939.
- Ban L et al. 2014. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 146 (1):76-84. Banerjee, A et al. 2019. Inflammatory
- Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. Endocrine, metabolic & immune disorders drug targets, 19(7), 959-974.
- Chermesh I & Eliakim R. 2004. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 36:551-2.
- Diav-Citrin O, et al. 1998. The safety of mesalamine in human pregnancy: a prospective controlled cohort study.

Gastroenterology; 114:23-28.

- Gaidos J. & Kane SV. 2020. Medication Adherence During Pregnancy in IBD: Compliance Avoids Complications. Digestive diseases and sciences, 10.1007/s10620-020-06271-w. Advance online publication.
- Hosseini-Carroll P, et al. 2015. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther. 6(4):156-171.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 168:1393-9.
- Källén B. 2014. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. Scand J Gastroenterol; 49(4):442-8.
- Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. Obstet Gynecol. 2015;126:401-12.
- Maliszewska, AM, et al. 2017. Inflammatory bowel disease and pregnancy. Ginekologia Polska, 88(7), 398-403.
- Marteau P & Devaux CB. 1994. Mesalazine during pregnancy. Lancet 344(8938):1708-1709.
- Moskovitz DN, et al. 2004. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99(4):656-661.
- Moretti ME. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. Theses Canada. Moretti ME, et al. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. J Clin Pharmacol. 38:867.
- Nelis GF. 1989. Diarrhoea due to 5-aminosalicylic acid in breastmilk. Lancet 1:383.
- Nielsen OH, et al. 2014. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 11(2):116-127.
- Norgård, B et al. 2003. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut, 52(2), 243-247.
- Pervez, H, et al. 2019. The Impact of Inflammatory Bowel Disease on Pregnancy and the Fetus: A Literature Review. Cureus, 11(9), e5648.
- Shin T, et al. 2014. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. Syst Biol Reprod Med. 60(6); 373-376.
- Silverman DA, et al. 2005. Is mesalazine really safe for use in breastfeeding mothers? Gut 54: 170-1.
- Watanabe, C. et al. 2020. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Digestive diseases and sciences, 10.1007/s10620-020-06221-6. Advance online publication.
- Wiersma TK, et al. 2022. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review. Pharmaceutics. 14(6):1241.
- Xu YL, et al. 2017. Inflammatory bowel disease in pregnancy: A report of 7 cases and review of the literature. Int J Clin Exp Med; 10:5525-32.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 avril 2026.

Toxoplasmosis

Selected References:

- Cahill JB, et al. 2005. Levofloxacin secretion in breast milk: a case report. *Pharmacotherapy*, 25(1):116-118.
- Giamarellou H, et al. 1989. Pharmacokinetics of three newer quinolones in pregnant and lactating women. *The American journal of medicine*, 87(5A):49S-51S.
- Gürpınar AN, et al. 1997. The effects of a fluoroquinolone on the growth and development of infants. *The Journal of international medical research*, 25(5):302-306.
- Meaney-Delman D, et al. 2013. Prophylaxis and treatment of anthrax in pregnant women. *Obstetrics and gynecology*, 122(4):885-900.
- Padberg S, et al. 2014. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. *Antimicrobial agents and chemotherapy*, 58(8):4392-4398.
- Shang J, et al. 2025. An Observational Study on the Pharmacokinetics of Levofloxacin in Lactating Atypical Pneumonia Patients. *Breastfeed Med*; 20(9):666-671.
- Toker SE, et al. 2021. Determination of levofloxacin by HPLC with fluorescence detection in human breast milk. *Bioanalysis*, 13(13):1063-1070.
- van den Oever HL, et al. 1998. Ciprofloxacin in preterm neonates: case report and review of the literature. *European journal of pediatrics*; 157(10):843-845.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 avril 2026.

Toxoplasmosis

Selected References:

- Bonnot O, et al. 2001. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. *J Clin Psychopharmacol*; 21(4):456-458.
- Brandlisuten RE, et al. 2017. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. *PLoS One*; 12(7):e0181042.
- Calderon-Margalit R, et al. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. *Am J Obstet Gynecol*; 201(6):579.e1-579.e8.
- Gandhi K, et al. 2023. Catatonia, Pregnancy, and Electroconvulsive Therapy (ECT). *Case Rep Psychiatry*; 7:2023:9601642.
- Iqbal MM, et al. 2002. Effects of commonly used benzodiazepines on the fetus, the neonate and the nursing infant. *Psychiatr Serv*; 53(1):39-49.
- Kargas GA et al. 1985. Perinatal mortality due to interaction of diphenhydramine and temazepam. *N Eng J Med*; 313(22):1417-1418.
- Kelly LE, et al. 2012. Neonatal Benzodiazepines Exposure during Breastfeeding. *J Pediatr*; 161(3):448-451.
- Lemmer P, et al. 2007. Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. *J Anal Toxicol*; 31(4):224-226.
- Meng LC, et al. 2024. Benzodiazepine Use During Pregnancy and Risk of Miscarriage. *JAMA Psychiatry*; 81(4):366-373.
- Nishimura A, et al. 2021. Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose. *Breastfeed Med*; 16(5):424-431.
- Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. *PLoS Med*; 19(3):e1003945.
- Oberlander TF, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. *Birth Defects Res B Dev Reprod Toxicol*; 83(1):68-76.
- Ornoy A, et al. 1998. Is benzodiazepine use during pregnancy really teratogenic? *Reprod Toxicol*; 12(5):511-515.
- Viggedal G, et al. 1993. Mental development in late infancy after prenatal exposure to benzodiazepines-prospective study. *J Child Psychol Psychiatry*; 34(3):295-305.
- Sheehy O, et al. 2019. Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion. *JAMA Psychiatry*; 76(9):948-957.
- Tinker SC, et al. 2019. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res Jun*, 1;111(10):613-620.
- U.S. Food and Drug Administration. 2023. Ativan label. Accessed September 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017794s049lbl.pdf. [Accessed April 2026]

- Whitelaw AG, et al. 1981. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed). 282(6270):1106-8.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 avril 2026.